Patents by Inventor Mauro Sergi
Mauro Sergi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210346287Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.Type: ApplicationFiled: April 19, 2021Publication date: November 11, 2021Applicant: Ablynx N.V.Inventors: Erik Depla, Mauro Sergi, Peter Casteels
-
Patent number: 11007146Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.Type: GrantFiled: April 24, 2017Date of Patent: May 18, 2021Assignee: Ablynx N.V.Inventors: Erik Depla, Mauro Sergi, Peter Casteels
-
Publication number: 20200392214Abstract: The present invention relates to an improved method for the manufacture of immunoglobulin single variable domains. More specifically, the present invention relates to a method of producing immunoglobulin single variable domains in which the proportion of carbamylated variants is strongly reduced or absent and to improved immunoglobulin single variable domains obtainable by methods of the present invention.Type: ApplicationFiled: August 2, 2019Publication date: December 17, 2020Applicant: Ablynx N.V.Inventors: Ann Brige, Bart Walcarius, Yves Meyvis, Mauro Sergi
-
Publication number: 20200062834Abstract: The present invention relates to an improved method for the manufacture of immunoglobulin single variable domains. More specifically, the present invention relates to a method of producing immunoglobulin single variable domains in which the proportion of carbamylated variants is strongly reduced or absent and to improved immunoglobulin single variable domains obtainable by methods of the present invention.Type: ApplicationFiled: August 2, 2019Publication date: February 27, 2020Applicant: Ablynx N.V.Inventors: Ann Brige, Bart Walcarius, Yves Meyvis, Mauro Sergi
-
Publication number: 20170333344Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.Type: ApplicationFiled: April 24, 2017Publication date: November 23, 2017Applicant: Ablynx N.V.Inventors: ERIK DEPLA, Mauro Sergi, Peter Casteels
-
Patent number: 9713589Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.Type: GrantFiled: February 11, 2011Date of Patent: July 25, 2017Assignee: Ablynx N.V.Inventors: Erik Depla, Mauro Sergi, Peter Casteels
-
Patent number: 8580733Abstract: The present invention is related to glucagon-like peptide-1 (GLP-1) and analogues insulinotropic peptides, monoconjugated to biocompatible polymeric molecules by enzymatic direct and site-specific transglutamination reaction as well as their pharmaceutical formulations and delivery systems for therapeutical application in dismetabolic pathologies such as type 2 diabetes.Type: GrantFiled: November 4, 2009Date of Patent: November 12, 2013Assignee: Bio-Ker SRLInventors: Giancarlo Tonon, Gaetano Orsini, Mauro Sergi, Rodolfo Schrepfer, Pierandrea Esposito
-
Publication number: 20130261288Abstract: The present disclosure relates to an improved method for the manufacture of immunoglobulin single variable domains. More specifically, the present disclosure relates to a method of producing immunoglobulin single variable domains in which the proportion of carbamylated variants is strongly reduced or absent and to improved immunoglobulin single variable domains obtainable by methods of the present disclosure.Type: ApplicationFiled: October 28, 2011Publication date: October 3, 2013Applicant: ABLYNX N.V.Inventors: Ann Brige, Bart Walcarius, Yves Meyvis, Mauro Sergi
-
Publication number: 20130019860Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.Type: ApplicationFiled: February 11, 2011Publication date: January 24, 2013Applicant: Ablynx N.V.Inventors: Erik Depla, Mauro Sergi, Peter Casteels
-
Publication number: 20110281797Abstract: The present invention is related to glucagon-like peptide-1 (GLP-1) and analogues insulinotropic peptides, monoconjugated to biocompatible polymeric molecules by enzymatic direct and site-specific transglutamination reaction as well as their pharmaceutical formulations and delivery systems for therapeutical application in dismetabolic pathologies such as type 2 diabetes.Type: ApplicationFiled: November 4, 2009Publication date: November 17, 2011Applicant: BIO-KER SRLInventors: Giancarlo Tonon, Gaetano Orsini, Mauro Sergi, Rodolfo Schrepfer, Pierandrea Esposito
-
Patent number: 7893019Abstract: Novel site-specific mono-conjugates of Granulocyte Colony Stimulating Factor (G-CSF) are hereby described, with analogues and derivatives thereof, which stimulate proliferation and differentiation of progenitor cells to mature neutrophiles. These conjugates have been obtained using transglutaminase to covalently and site-specifically bind a hydrophilic, non-immunogenic polymer to a single glutamine residue of the human G-CSF native sequence and analogues thereof. These novel site-specific mono-conjugated derivatives are recommended for therapeutic use since they are stable in solution and exhibit significant biological activity in vitro and a longer bloodstream half-life, as compared to the non-conjugated protein, with a consequent prolonged pharmacological activity.Type: GrantFiled: July 30, 2007Date of Patent: February 22, 2011Assignee: Bio-Ker S.r.l.Inventors: Giancarlo Tonon, Gaetano Orsini, Rodolfo Schrepfer, Geoffrey Taylor, Mauro Sergi
-
Publication number: 20100029555Abstract: Novel site-specific mono-conjugates of Granulocyte Colony Stimulating Factor (G-CSF) are hereby described, with analogues and derivatives thereof, which stimulate proliferation and differentiation of progenitor cells to mature neutrophiles. These conjugates have been obtained using transglutaminase to covalently and site-specifically bind a hydrophilic, non-immunogenic polymer to a single glutamine residue of the human G-CSF native sequence and analogues thereof. These novel site-specific mono-conjugated derivatives are recommended for therapeutic use since they are stable in solution and exhibit significant biological activity in vitro and a longer bloodstream half-life, as compared to the non-conjugated protein, with a consequent prolonged pharmacological activity.Type: ApplicationFiled: July 30, 2007Publication date: February 4, 2010Applicant: Bio-Ker S.r.lInventors: Giancarlo Tonon, Gaetano Orsini, Rodolfo Schrepfer, Geoffrey Taylor, Mauro Sergi